Jim Datin, the CEO of BioAgilytix, grew his company's revenue from $10.4 million in 2014 to $35.9 million in 2017, a 245% increase, and to just under $60 million in 2018.  

BioAgilytix is a bioanalytical testing laboratory specializing in large molecule bioanalysis.  

In this interview with Eversprint's Malcolm Lui, Jim shares how he and his team accelerated their high value sales by:  

• Building a team of renowned experts who put customers first, as indicated by their 99% customer retention rate.
• Riding the trend toward large molecule bioanalysis that is expected to continue for years to come.
• Providing a cost effective bioanalytical testing service to the largest pharmaceutical and biotech companies in the world.